The pan-PPAR agonist lanifibranor reduces development of lung fibrosis and attenuates cardiorespiratory manifestations in a transgenic mouse model of systemic sclerosis. (2021)

First Author: Derrett-Smith E
Attributed to:  Functional and molecular diversity of skin fibroblasts in systemic sclerosis. funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1186/s13075-021-02592-x

PubMed Identifier: 34488870

Publication URI: http://europepmc.org/abstract/MED/34488870

Type: Journal Article/Review

Volume: 23

Parent Publication: Arthritis research & therapy

Issue: 1

ISSN: 1478-6354